Which adverse effect is described for evinacumab?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Fatigue is a common, systemic adverse effect seen with monoclonal antibody therapies like evinacumab. In clinical studies, patients receiving evinacumab frequently report feeling unusually tired, and this fatigue is typically mild to moderate and manageable. This reflects the body’s overall response to a biologic than any single organ-specific toxicity. While other adverse events such as nasal symptoms or headaches can occur with various treatments, fatigue tends to be the more consistently described systemic side effect with evinacumab. Severe hypersensitivity reactions are possible with monoclonal antibodies but are less common, so fatigue remains the adverse effect most characteristically described for this medication.